AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22149546 — intervention group
Group type: EXPERIMENTAL
Intervention: hsCRP
Number of subjects: 200
Study 22149546 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte count
Number of subjects: 200
Study 20223100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingestion of nonalcoholic wine
Number of subjects: 12
Study 20223100 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of mouthwash
Number of subjects: 12
Study 18566924 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counseling program (30 min walking 5 days a week and 15 min lower-limb strength training 3 days a week)
Number of subjects: 400
Study 18566924 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study 15684252 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 30
Study 15684252 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia
Number of subjects: 30
Study 15684252 — intervention group
Group type: COMPARATOR
Intervention: Control (age-matched subjects)
Number of subjects: 30
Study 11934200 — intervention group
Group type: EXPERIMENTAL
Intervention: PRK
Number of subjects: 15
Study 11934200 — intervention group
Group type: EXPERIMENTAL
Intervention: LASEK
Number of subjects: 15
Study 10444055 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric multifocal back surface RGP contact lens
Number of subjects: 28
Study 7576895 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium supplemented formula (17 micrograms Se/L)
Number of subjects: 44
Study 7576895 — intervention group
Group type: COMPARATOR
Intervention: Unsupplemented formula (4.6 micrograms Se/L)
Number of subjects: 44
Study 2156764 — intervention group
Group type: EXPERIMENTAL
Intervention: Human leukocyte interferon cream (IFN) - 9 x 10(6) IU applied deep into the vagina every night for 2-week courses 1 week apart, for a total treatment period of 12 months.
Number of subjects: 20
Study 2156764 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 20
Study 372222 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxi/Ferm identification system
Number of subjects: 96
Study 372222 — intervention group
Group type: COMPARATOR
Intervention: Conventional test battery
Number of subjects: 96
Study 30860009 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperTowel® (ST1)
Number of subjects: 32
Study 30860009 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperTowel® (ST2)
Number of subjects: 32
Study 30860009 — intervention group
Group type: EXPERIMENTAL
Intervention: SuperTowel® (ST3)
Number of subjects: 32
Study 30860009 — intervention group
Group type: COMPARATOR
Intervention: Soap (control)
Number of subjects: 32
Study 28616651 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block (TAP block)
Number of subjects: 90
Study 28616651 — intervention group
Group type: EXPERIMENTAL
Intervention: Iliohypogastric/ilioinguinal nerve block (IHINB)
Number of subjects: 90
Study 28616651 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nerve block)
Number of subjects: 90
Study 25052844 — intervention group
Group type: EXPERIMENTAL
Intervention: iTrainer (iT)
Number of subjects: 45
Study 25052844 — intervention group
Group type: COMPARATOR
Intervention: Standard Pelvic Trainer (SPT)
Number of subjects: 45
Study 23776033 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day for 14 days
Number of subjects: 38
Study 23776033 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 21562449 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (mean level 7.2 ± 2.54 ng/mL)
Number of subjects: 998
Study 21562449 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) (mean dose 1.5 ± 0.61 g/day)
Number of subjects: 998
Study 21562449 — intervention group
Group type: EXPERIMENTAL
Intervention: Other variables (acute rejection, donor age, delayed graft function)
Number of subjects: 998
Study 21562449 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage II CKD (60‐89 mL/min) and Stage III CKD (30‐59 mL/min)
Number of subjects: 998
Study 19501034 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management educational program (6 months, 5 components: background, medication, physical exercise, nutrition, blood glucose self-monitoring)
Number of subjects: 25
Study 19501034 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management educational program (6 months)
Number of subjects: 25
Study 16490760 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium gluconate (i.v. bolus of 0.21 mmol kg(‐1) followed by a continuous infusion of 0.03 mmol(‐1) kg(‐1) h(‐1))
Number of subjects: 40
Study 16490760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15311667 — intervention group
Group type: EXPERIMENTAL
Intervention: Object file continuity
Number of subjects: 0
Study 15311667 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervening stream items between T1 and T2
Number of subjects: 0
Study 11369255 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery during the menstrual cycle phase with ovulation
Number of subjects: 0
Study 9549961 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Number of subjects: 56
Study 9549961 — intervention group
Group type: COMPARATOR
Intervention: Attention-placebo control
Number of subjects: 56
Study 7839784 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg.kg‐1 of racemic ketamine
Number of subjects: 50
Study 7839784 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.kg‐1 of S‐(+) ketamine
Number of subjects: 50
Study 7839784 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mg.kg‐1 of midazolam (prior administration)
Number of subjects: 50
Study 3277779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg boluses every 6 hours
Number of subjects: 0
Study 3277779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine infusion (125 micrograms/kg.h)
Number of subjects: 0
Study 3277779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine infusion (250 micrograms/kg.h)
Number of subjects: 0
Study 3277779 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 1464545 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (depot injection every 28 days)
Number of subjects: 589
Study 1464545 — intervention group
Group type: COMPARATOR
Intervention: Zoladex plus flutamide (3 x 250 mg tablets daily)
Number of subjects: 589
Study 1464545 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 589
Study 1464545 — intervention group
Group type: COMPARATOR
Intervention: Zoladex plus flutamide
Number of subjects: 589
Study 889333 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tretinoin 0.1% cream
Number of subjects: 40
Study 889333 — intervention group
Group type: COMPARATOR
Intervention: Salicylic acid 2% cream
Number of subjects: 40
Study 31213045 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic needle tip positioning (DNTP)
Number of subjects: 136
Study 31213045 — intervention group
Group type: COMPARATOR
Intervention: Conventional long-axis in-plane (LAX-IP)
Number of subjects: 136
Study 30676790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery during the 1-child policy period (January 2013-September 2014)
Number of subjects: 27977
Study 30676790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery during the selective 2-child policy period (October 2014-July 2016)
Number of subjects: 27977
Study 30676790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery during the universal 2-child policy period (August 2016-December 2016)
Number of subjects: 27977
Study 30676790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery on maternal request
Number of subjects: 27977
Study 30676790 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery indicated by a previous cesarean delivery
Number of subjects: 27977
Study 30676790 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of medical necessity of cesareans by experts
Number of subjects: 27977
Study 27459673 — intervention group
Group type: EXPERIMENTAL
Intervention: Altitude training at 2200m (ALT, n = 5)
Number of subjects: 10
Study 27459673 — intervention group
Group type: COMPARATOR
Intervention: Control group at 600m (CON, n = 5)
Number of subjects: 10
Study 26040302 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 494
Study 26040302 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 494
Study 26040302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 494
Study 23549424 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular repair (EVAR)
Number of subjects: 116
Study 23549424 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR)
Number of subjects: 116
Study 23549424 — intervention group
Group type: COMPARATOR
Intervention: Nonrandomized cohort (surgically treated patients)
Number of subjects: 116
Study 23549424 — intervention group
Group type: COMPARATOR
Intervention: Open repair (OR) in patients with unfavorable anatomy for EVAR
Number of subjects: 116
Study 21551987 — intervention group
Group type: EXPERIMENTAL
Intervention: Fall prevention program (12-week group program and 8-week self-management program using a health calendar)
Number of subjects: 53
Study 19758429 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-collar/housewife status
Number of subjects: 220
Study 19758429 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI > or = 30 kg/m2
Number of subjects: 220
Study 19758429 — intervention group
Group type: EXPERIMENTAL
Intervention: Sibling history of CTS
Number of subjects: 220
Study 19758429 — intervention group
Group type: EXPERIMENTAL
Intervention: Coexistence of trigger finger
Number of subjects: 220
Study 19758429 — intervention group
Group type: EXPERIMENTAL
Intervention: Height (women > or = 165 cm; men > or = 175 cm)
Number of subjects: 220
Study 19758429 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of biomechanical risk factors (frequent repetitivity and sustained force)
Number of subjects: 220
Study 17227802 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral alendronate 70 mg/wk
Number of subjects: 31
Study 17227802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 14633757 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. midazolam sedation (titrated at 0.5 mg x min(‐1), maximum 5 mg)
Number of subjects: 40
Study 14633757 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide/oxygen sedation (titrated to 30%/70%)
Number of subjects: 40
Study 14633757 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. midazolam sedation
Number of subjects: 40
Study 14633757 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide/oxygen sedation
Number of subjects: 40
Study 14633757 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 40
Study 10947321 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI)
Number of subjects: 20
Study 10947321 — intervention group
Group type: EXPERIMENTAL
Intervention: Jet Nebulizer
Number of subjects: 20
Study 10947321 — intervention group
Group type: COMPARATOR
Intervention: Patient Preference
Number of subjects: 20
Study 8648308 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total knee arthroplasty in obese patients
Number of subjects: 45
Study 8648308 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonobese patients)
Number of subjects: 45
Study 8648308 — intervention group
Group type: COMPARATOR
Intervention: Both groups (obese and control)
Number of subjects: 45
Study 1613808 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic hypothermia (cooling to 30-32 degrees C for 1-8 hours, mean 4 hours)
Number of subjects: 21
Study 1613808 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooling to levels below 32 degrees C
Number of subjects: 21
Study 1613808 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine potassium replacement for asymptomatic hypokalemia
Number of subjects: 21
Study 1613808 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface cooling to a core temperature of 32 degrees C for 48 hours
Number of subjects: 21
Study 6378239 — intervention group
Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (RIT 4199)
Number of subjects: 29
Study 6378239 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-adapted recombinant virus vaccine (A/Washington/80, H3N2)
Number of subjects: 29
Study 30078335 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized environmental report back intervention (free air nicotine and radon home test kits, brief problem-solving phone intervention)
Number of subjects: 515
Study 30078335 — intervention group
Group type: COMPARATOR
Intervention: Control group (coupon for free test kits)
Number of subjects: 515
Study 28158398 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 0
Study 28158398 — intervention group
Group type: COMPARATOR
Intervention: Enalapril
Number of subjects: 0
Study 25925687 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus withdrawal
Number of subjects: 14
Study 23913722 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferring control to God
Number of subjects: 192
Study 23913722 — intervention group
Group type: COMPARATOR
Intervention: Active coping style
Number of subjects: 192
Study 21802625 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma fibrin matrix (PRPFM) construct augmentation
Number of subjects: 40
Study 21802625 — intervention group
Group type: COMPARATOR
Intervention: Rotator cuff repairs without PRPFM augmentation (control group)
Number of subjects: 40
Study 21802625 — intervention group
Group type: EXPERIMENTAL
Intervention: American Shoulder and Elbow Surgeons score
Number of subjects: 40
Study 21802625 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Assessment Numeric Evaluation score
Number of subjects: 40
Study 21802625 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple Shoulder Test score
Number of subjects: 40
Study 21802625 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant score
Number of subjects: 40
Study 21802625 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowe score
Number of subjects: 40
Study 19254354 — intervention group
Group type: COMPARATOR
Intervention: 300 mg Acotiamide
Number of subjects: 71
Study 19254354 — intervention group
Group type: COMPARATOR
Intervention: 100 mg Acotiamide
Number of subjects: 71
Study 16896273 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg and Atorvastatin 10 mg
Number of subjects: 847
Study 16896273 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 847
Study 16896273 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 847
Study 16896273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 847
Study 15145925 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (90 min cycling at 85% lactate threshold)
Number of subjects: 20
Study 15145925 — intervention group
Group type: COMPARATOR
Intervention: Rest (semirecumbent)
Number of subjects: 20
Study 10900369 — intervention group
Group type: EXPERIMENTAL
Intervention: Transmural home care intervention programme
Number of subjects: 116
Study 10900369 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 116
Study 9310278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (eicosapentaenoic acid, 1.08 g/day)
Number of subjects: 360
Study 9310278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mustard oil (alpha-linolenic acid, 2.9 g/day)
Number of subjects: 360
Study 9310278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 8449054 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, 250 mg twice a day for 7 to 14 days
Number of subjects: 268
Study 8449054 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate, 500 mg 4 times a day for 7 to 14 days
Number of subjects: 268
Study 3819391 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5 mg t.i.d. for 3 days
Number of subjects: 10
Study 29064206 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg vitamin B3 daily for 1 week
Number of subjects: 20
Study 29064206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28854066 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin (1.4 mg/m2 intravenously on days 1 and 8 every 21 days)
Number of subjects: 0
Study 28854066 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine (850, 1,000, or 1,200 mg/m2 intravenously on day 1 every 21 days)
Number of subjects: 0
Study 28854066 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 0
Study 28854066 — intervention group
Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 0
Study 25953506 — intervention group
Group type: COMPARATOR
Intervention: Conventional shoes (CONV)
Number of subjects: 26
Study 25953506 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalistic shoes (MIN)
Number of subjects: 26
Study 25953506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigued state
Number of subjects: 26
Study 25953506 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue
Number of subjects: 26
Study 23477634 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Number of subjects: 20211
Study 23477634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20211
Study 21320346 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment of malaria in infants (IPTi) with sulphadoxine‐pyrimethamine (SP) administered at the time of routine vaccinations.
Number of subjects: 0
Study 21320346 — intervention group
Group type: COMPARATOR
Intervention: Non-implementing health centres (Control)
Number of subjects: 0
Study 19223984 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 kcal/kg/week exercise (n = 139)
Number of subjects: 411
Study 19223984 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 kcal/kg/week exercise (n = 85)
Number of subjects: 411
Study 19223984 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 kcal/kg/week exercise (n = 93)
Number of subjects: 411
Study 19223984 — intervention group
Group type: COMPARATOR
Intervention: Non-exercise control (n = 94)
Number of subjects: 411
Study 19223984 — intervention group
Group type: EXPERIMENTAL
Intervention: All exercise groups
Number of subjects: 411
Study 16543297 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support intervention delivered to nursing home staff over 10 months, focusing on alternatives to drugs for the management of agitated behaviour in dementia
Number of subjects: 12
Study 16543297 — intervention group
Group type: COMPARATOR
Intervention: Control homes
Number of subjects: 12
Study 14767435 — intervention group
Group type: EXPERIMENTAL
Intervention: AIC (0.06-12 microg, n = 28)
Number of subjects: 57
Study 14767435 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 29)
Number of subjects: 57
Study 11168210 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-retained mandibular overdenture (IRO)
Number of subjects: 90
Study 11168210 — intervention group
Group type: EXPERIMENTAL
Intervention: Preprosthetic surgery to enlarge the denture‐bearing area (PPS)
Number of subjects: 90
Study 11168210 — intervention group
Group type: COMPARATOR
Intervention: Construction of a new set of dentures (CD)
Number of subjects: 90
Study 9399292 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and/or exercise intervention during 1990-1991
Number of subjects: 200
Study 9399292 — intervention group
Group type: EXPERIMENTAL
Intervention: Current physical self-perceptions
Number of subjects: 200
Study 9399292 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-perception model, Health Belief model, Self-efficacy model
Number of subjects: 200
Study 9399292 — intervention group
Group type: EXPERIMENTAL
Intervention: Outcome Expectations, Compliance Self-efficacy, Perceived Fitness, Exercise Mastery
Number of subjects: 200
Study 8250308 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine added to general anesthesia
Number of subjects: 22
Study 8250308 — intervention group
Group type: COMPARATOR
Intervention: Standardized general anesthesia (control group)
Number of subjects: 22
Study 3307423 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent nursing contact, education in preterm labor symptoms, and self‐palpation of uterine activity (group E, n = 50)
Number of subjects: 157
Study 3307423 — intervention group
Group type: COMPARATOR
Intervention: Daily nursing contact, preterm labor education, and the Term Guard home uterine activity monitor (group EM, n = 107)
Number of subjects: 157
Study 30322751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4 (500 mL bolus)
Number of subjects: 43
Study 30322751 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate (1000 mL bolus)
Number of subjects: 43
Study 30322751 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate (control group)
Number of subjects: 43
Study 30322751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch 130/0.4
Number of subjects: 43
Study 28835401 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Number of subjects: 0
Study 26420182 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated kiwifruit extract (1 g/day)
Number of subjects: 40
Study 26420182 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 23957631 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (Bifidobacterium longum and inulin-based prebiotic Synergy 1)
Number of subjects: 43
Study 23957631 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 43
Study 21402860 — intervention group
Group type: EXPERIMENTAL
Intervention: 200‐mg rifamycin SV MMX modified‐release tablets
Number of subjects: 2
Study 18496232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (1 mg/kg/d)
Number of subjects: 22
Study 18496232 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (9 mg/d)
Number of subjects: 22
Study 18496232 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (after switching from Budesonide)
Number of subjects: 22
Study 16569361 — intervention group
Group type: EXPERIMENTAL
Intervention: 50mg Etanercept BIW
Number of subjects: 108
Study 16569361 — intervention group
Group type: EXPERIMENTAL
Intervention: 100mg Etanercept OW
Number of subjects: 108
Study 12714403 — intervention group
Group type: COMPARATOR
Intervention: Viscocanalostomy
Number of subjects: 40